A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale

详细信息    查看全文

• 作者：Liang Zhao^a ; Antonino S. Cavallaro^b ; David Wibowo^a ; Bing Zhang^c ; Jun Zhang^a ; Neena Mitter^b ; Chengzhong Yu^a ; Chun-Xia Zhao^a ; ^{z.chunxia@uq.edu.au} ; Anton P.J. Middelberg^a ; ^{a.middelberg@uq.edu.au}
• 关键词：Anaplasma marginale ; Partially-purified antigens ; Aggregates ; Endotoxin ; Silica vesicles ; Immunogenicity
• 刊名：Vaccine
• 出版年：2017
• 出版时间：3 January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：77-83
• 全文大小：1050 K
• 卷排序：35

文摘

Anaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved higher antibody and cell-mediated immune responses compared to the purified ones. This finding suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to finding a “Goldilocks” level of contaminants. The new nanovaccine formulation using partially-purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper veterinary vaccines.